Pfizer Inc. — IBRANCE (palbociclib) in combination with tr · HR+, HER2+ Metastatic Breast Cancer.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/7/26) through T+5. Run-up high $28.55 on 4/6/26, low $24.72 on 6/23/26 (T-120 to T-1). FDA decision 6/24/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-24
OutcomeApproved
Drug / candidateIBRANCE (palbociclib) in combination with tr